Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GrifolsGRFS +0.53%82 Earnings per Share (Diluted) is $0.71 as of Mar. 2026. GuruFocus rates GRFS with a GF Score™ of 82/100 and a GF Value™ of $9.77 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 788 Drug Manufacturers companies, Grifols ranks better than 80.46% on this metric.
Grifols's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.12.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.71.
Grifols's EPS without NRI for the
three
months ended in Mar. 2026 was $0.12.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.72.
During the past 12 months, Grifols's average EPS without NRIGrowth Rate was 114.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 35.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -7.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -14.30% per year.
During the past 13 years, Grifols's highest 3-Year average EPS without NRI Growth Rate was 86.80% per year. The lowest was -54.60% per year. And the median was 6.00% per year.
Grifols (NAS:GRFS) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Grifols Earnings per Share (Diluted) Related Terms
Grifols Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Grifols's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRFS vs LLY, JNJ, ABBV: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - General subindustry, Grifols's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's PE Ratio distribution charts can be found below:
* The bar in red indicates where Grifols's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Grifols's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.71 mean?
Grifols (GRFS) has a Earnings per Share (Diluted) of $0.71 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Grifols and its competitors. According to the industry distribution chart, Grifols ranks #154 out of 788 companies in the Drug Manufacturers industry, placing it in the top 19.5%.
Is Grifols' Earnings per Share (Diluted) too high?
Grifols' current Earnings per Share (Diluted) is $0.71. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.60. Grifols' value of $0.71 is 92.6% below this industry median. Based on the distribution chart, Grifols ranks #154 out of 788 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grifols has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Earnings per Share (Diluted) compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #154 out of 788 companies for Earnings per Share (Diluted). This places Grifols in the top 20% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 9.60. Grifols' value of $0.71 is 92.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Earnings per Share (Diluted) of $0.71 is 92.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Earnings per Share (Diluted) is $0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.77, compared to a current price of $7.60 — trading 22.3% below its estimated fair value. The current Earnings per Share (Diluted) is $0.71 and 92.6% below the Drug Manufacturers industry median of 9.60. Grifols' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Grifols (GRFS), the current Earnings per Share (Diluted) is $0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.60 is trading 22.3% below its estimated GF Value™ of $9.77.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
Earnings per Share (Diluted): $0.71
GF Value™: $9.77 vs. price of $7.60 (22.3% below fair value)
Industry Position: 92.6% below the Drug Manufacturers median (#154 of 788)
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
82GF Score
Get the complete analysis for GRFS
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
